JW (Cayman) Therapeutics Co. Ltd. · HKEX:2126
JW (Cayman) Therapeutics — Investor Presentation (November 2026)
21 slides from JW (Cayman) Therapeutics's investor presentation, Nov 15, 2026
Slide 1: Inside Information: Investor Presentation on Inclusion of CARTEYVA in NRDL
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in relia
Slide 2: Announcement notices and cautionary statement
Overseas/International dial-in (+852) 51089680 (Hong Kong, China) (+886) 277083288 (Taiwan, China) (+86) 1021377168 (Global) (+1) 2087016888 (USA) Password: 706797 Further, to ensure that all shareholders and potential investors of the Company have equal and timely access to such information, the Co
Slide 3: CARTEYVA NRDL Inclusion and Corporate Update
Innovating cures, shaping what’s next CARTEYVA® NRDL Inclusion and Corporate Update JW Therapeutics (HKEX: 2126) | Investor Update 15 November 2026 All rights reserved. No reproduction or distribution without authorization. For investor communication purposes only. 1
Slide 4: Disclaimer
Disclaimer The information in this presentation has been prepared by representatives of JW (Cayman) Therapeutics Co. Ltd (the “Company” and, together with its subsidiaries, the “Group”) for use in presentations by the Group for information purposes only. By attending the meeting where this presentat
Slide 5: Agenda
Agenda 1 A milestone for CAR-T cell therapy in China The only CAR-T included in basic NRDL; cost optimization and manufacturing excellence support sustained growth 2 JWCAR239: a potential first-in-class dual-target, dual-armored CAR-T Clinical progress and preliminary data 3 Proprietary differentiat
Slide 6: CARTEYVA is the only CAR-T included in China's basic NRDL
CARTEYVA® is the only CAR-T included in China's basic NRDL, marking a breakthrough inflection point for CAR-T in China Large B-cell Lymphoma NRDL Breakthrough 288,600 Follicular Lymphoma A New Era for CAR-T in China RMB Mantle Cell Lymphoma NRDL Reimbursement Price All three lymphoma indications eff
Slide 7: NRDL inclusion brings CAR-T to more patients in China
NRDL inclusion brings CAR-T to more patients in China and unlocks substantial market potential Following NRDL inclusion, CARTEYVA® Limited accessibility is the key barrier for CAR-T treatment in China is expected to benefit more eligible Commercial CAR-T penetration in China lags far behind mature m
Slide 8: Cost optimization supports NRDL pricing, LVV technology validates quality
Cost optimization supports NRDL pricing, globally recognized LVV technology validates the reliable product quality Management expects CARTEYVA® unit manufacturing cost to decline by >65% after cost optimization, supporting NRDL pricing and positive unit economics Manufacturing cost optimization leve
Slide 9: Efficient manufacturing and reliable delivery underpin CAR-T manufacturing advantage
Efficient manufacturing and reliable delivery underpin JW's CAR-T manufacturing advantage The only* 50% > 99% > 80% Approved manufacturer to 50% lower staffing needs — Industry-leading one-time Over 80% production produce CAR-T products for modular suite design drives pass manufacturing automation r
Slide 10: Agenda
Agenda 1 A milestone for CAR-T cell therapy in China The only CAR-T included in basic NRDL; cost optimization and manufacturing excellence support sustained growth 2 JWCAR239: a potential first-in-class dual-target, dual-armored CAR-T Clinical progress and preliminary data 3 Proprietary differentiat
Slide 11: Innovative cell therapy pipeline
Innovative cell therapy pipeline Autologous Autologous In vivo CAR-T CAR-T platform TCR-T platform platform Program Target Target indication Preclinical IIT IND Phase 1 Registrational NDA Approved Partner ≥3L LBCL, ≥3L FL, ≥3L MCL 2L LBCL CARTEYVA® CD19 SLE SSc Dual-armored JWCAR239 CD19/CD20 LBCL N
Slide 12: JWCAR239: proprietary CD19/CD20 dual-armored CAR-T
JWCAR239: JW's proprietary CD19/CD20 dual-armored CAR-T, designed for CAR-T-resistant patients JWCAR239 A differentiated mechanism Significant unmet need Built on JW’s clinically validated CAR-T designed for CAR-T-resistant patients R&D and manufacturing platform ~50% of patients relapse or are refr
Slide 13: Agenda
Agenda 1 A milestone for CAR-T cell therapy in China The only CAR-T included in basic NRDL; cost optimization and manufacturing excellence support sustained growth 2 JWCAR239: a potential first-in-class dual-target, dual-armored CAR-T Clinical progress and preliminary data 3 Proprietary differentiat
Slide 14: Differentiated in vivo LVV delivery: in vitro data
Differentiated in vivo LVV delivery: in vitro data support the feasibility of targeted in vivo delivery Develop in vivo CAR-T based on established LVV In vitro data show low off-target transduction, efficient resting T-cell transduction and strong R&D and manufacturing capabilities serum stability w
Slide 15: In vivo CAR-T platform: mouse proof-of-concept data
In vivo CAR-T platform: mouse proof-of-concept data Model: Nalm-6 + hPBMC Group: Vehicle LVV-P1 (1E7) LVV-P2 (1E7) CAR-T cells generated in vivo and tumor growth controlled with a single LVV dose, with consistent results across two vector manufacturing processes D-1 D6 Tumor burden CAR-T cells D13 V
Slide 16: Agenda
Agenda 1 A milestone for CAR-T cell therapy in China The only CAR-T included in basic NRDL; cost optimization and manufacturing excellence support sustained growth 2 JWCAR239: a potential first-in-class dual-target, dual-armored CAR-T Clinical progress and preliminary data 3 Proprietary differentiat
Slide 17: JW and Eureka sign a license and assignment agreement
JW and Eureka sign a license and assignment agreement, reinforcing focus on core innovations Overview Announcement date: 9 November 2026 Geographic scope JW Therapeutics to transfer its exclusive development and commercialization rights in Greater China and ASEAN for its AFP- Greater China and GPC3-
Slide 18: Agenda
Agenda 1 A milestone for CAR-T cell therapy in China The only CAR-T included in basic NRDL; cost optimization and manufacturing excellence support sustained growth 2 JWCAR239: a potential first-in-class dual-target, dual-armored CAR-T Clinical progress and preliminary data 3 Proprietary differentiat
Slide 19: Strategic Outlook: Commercial Growth and Pipeline Innovation
Strategic Outlook: Commercial Growth and Pipeline Innovation 2027-2029 NRDL Inclusion Drives Commercial Scale-Up and Financial Progress NRDL implementation expands access to CARTEYVA® and drives substantial Progressing Toward NRDL Inclusion patient-volume growth. Economies of scale and lower manufac
Slide 20: Summary
Summary Certainty Scarcity Superiority Value foundation Value moat Value upside • NRDL implementation marks a commercial • The only CAR-T included in China's basic • Potential first-in-class CAR-T inflection point NRDL innovation CARTEYVA® is the sole CAR-T in the basic NRDL, A clear first-mover adv
Slide 21: Innovating cures, shaping what's next
Innovating cures, shaping what’s next
JW (Cayman) Therapeutics — Investor Presentation (November 2026) on 6ix